Euroopa Liit -
eesti -
EMA (European Medicines Agency)
copiktra
secura bio limited - duvelisib - leukemia, lymphocytic, chronic, b-cell; lymphoma, follicular - antineoplastilised ained - copiktra monotherapy is indicated for the treatment of adult patients with: relapsed or refractory chronic lymphocytic leukaemia (cll) after at least two prior therapies. follicular lymphoma (fl) that is refractory to at least two prior systemic therapies.
Eesti -
eesti -
Ravimiamet
eritromicina normon 500mg tablett
laboratorios normon s.a. - erütromütsiin - tablett - 500mg 30tk
Euroopa Liit -
eesti -
EMA (European Medicines Agency)
qinlock
deciphera pharmaceuticals (netherlands) b.v. - ripretinib - seedetraktist esinevad stromaal-kasvajad - antineoplastilised ained - qinlock is indicated for the treatment of adult patients with advanced gastrointestinal stromal tumour (gist) who have received prior treatment with three or more kinase inhibitors, including imatinib.
Euroopa Liit -
eesti -
EMA (European Medicines Agency)
koselugo
astrazeneca ab - selumetinib sulfate - neurofibromatosis 1 - antineoplastilised ained - koselugo as monotherapy is indicated for the treatment of symptomatic, inoperable plexiform neurofibromas (pn) in paediatric patients with neurofibromatosis type 1 (nf1) aged 3 years and above.
Eesti -
eesti -
Ravimiamet
erythromycine bailleul 4% nahalahus
laboratoires opodex industrie - erütromütsiin - nahalahus - 4% 100ml 1tk
Eesti -
eesti -
Ravimiamet
erythromycin stragen infusioonilahuse pulber
fisiopharma - erütromütsiin - infusioonilahuse pulber - 1g 10tk
Eesti -
eesti -
Ravimiamet
erythromycin inresa infusioonilahuse pulber
inresa arzneimittel gmbh - erütromütsiin - infusioonilahuse pulber - 1g 10tk
Eesti -
eesti -
Ravimiamet
eritromicina lattobionato fisiopharma süstelahuse pulber ja lahusti
fisiopharma - erütromütsiin - süstelahuse pulber ja lahusti - 1g 1tk
Euroopa Liit -
eesti -
EMA (European Medicines Agency)
padcev
astellas pharma europe b.v. - enfortumab vedotin - carcinoma, transitional cell; urologic neoplasms - antineoplastilised ained - padcev as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a platinum-containing chemotherapy and a programmed death receptor 1 or programmed death ligand 1 inhibitor.
Eesti -
eesti -
Ravimiamet
inderm nahalahus
mibe gmbh arzneimittel - erütromütsiin - nahalahus - 10mg 1g 50ml 1tk